CN100349884C - 3－苯基呋喃－2－酮衍生物作为环加氧酶的抑制剂 - Google Patents

3－苯基呋喃－2－酮衍生物作为环加氧酶的抑制剂 Download PDF

Info

Publication number
CN100349884C
CN100349884C CNB2004800096102A CN200480009610A CN100349884C CN 100349884 C CN100349884 C CN 100349884C CN B2004800096102 A CNB2004800096102 A CN B2004800096102A CN 200480009610 A CN200480009610 A CN 200480009610A CN 100349884 C CN100349884 C CN 100349884C
Authority
CN
China
Prior art keywords
compound
formula
phenylfuran
cox
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800096102A
Other languages
English (en)
Chinese (zh)
Other versions
CN1771240A (zh
Inventor
J·F·卡图尔拉雅瓦洛耶斯
G·沃尔罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Almirall Prodesfarma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Prodesfarma SA filed Critical Almirall Prodesfarma SA
Publication of CN1771240A publication Critical patent/CN1771240A/zh
Application granted granted Critical
Publication of CN100349884C publication Critical patent/CN100349884C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
CNB2004800096102A 2003-02-13 2004-02-12 3－苯基呋喃－2－酮衍生物作为环加氧酶的抑制剂 Expired - Fee Related CN100349884C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESES200300353 2003-02-13
ES200300353 2003-02-13
ES200300353A ES2214129B1 (es) 2003-02-13 2003-02-13 3-fenilfuran-2-onas.

Publications (2)

Publication Number Publication Date
CN1771240A CN1771240A (zh) 2006-05-10
CN100349884C true CN100349884C (zh) 2007-11-21

Family

ID=32865134

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800096102A Expired - Fee Related CN100349884C (zh) 2003-02-13 2004-02-12 3－苯基呋喃－2－酮衍生物作为环加氧酶的抑制剂

Country Status (6)

Country Link
US (1) US20060189684A1 (enExample)
EP (1) EP1592678A1 (enExample)
JP (1) JP2006517561A (enExample)
CN (1) CN100349884C (enExample)
ES (1) ES2214129B1 (enExample)
WO (1) WO2004072057A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2214130B1 (es) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 2-3'-bipiridinas.
ES2213485B1 (es) 2003-02-13 2005-12-16 Almirall Prodesfarma, S.A. Derivados de la 2-fenilpiran-4-ona.
BRPI0607017B8 (pt) * 2005-04-06 2021-05-25 Adamas Pharmaceuticals Inc composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
US20150126573A1 (en) 2012-05-09 2015-05-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
EP3883562A4 (en) 2018-11-21 2022-08-03 Tremeau Pharmaceuticals, Inc. PURIFIED FORMS OF ROFECOXIB AND METHODS OF MAKING AND USING
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492416B1 (en) * 1999-04-14 2002-12-10 Pacific Corporation 4,5-diaryl-3(2H)-furanone derivatives as cyclooxygenase-2 inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486194B2 (en) * 1993-06-24 2002-11-26 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US6231888B1 (en) * 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
EP0889878B1 (en) * 1996-03-29 2002-09-04 Merck Frosst Canada & Co. Bisarylcyclobutene derivates as cyclooxygenase inhibitors
KR100373622B1 (ko) * 1996-05-17 2003-07-12 머크 앤드 캄파니 인코포레이티드 사이클로옥시게나제-2로매개된질환의1일1회치료용조성물
US6307047B1 (en) * 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
ATE281458T1 (de) * 1997-09-05 2004-11-15 Glaxo Group Ltd Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate
US5994379A (en) * 1998-02-13 1999-11-30 Merck Frosst Canada, Inc. Bisaryl COX-2 inhibiting compounds, compositions and methods of use
JP2002517423A (ja) * 1998-06-08 2002-06-18 アドバンスド メディスン インコーポレーテッド シクロオキシゲナーゼ−２の多結合インヒビター
KR100295206B1 (ko) * 1998-08-22 2001-07-12 서경배 디아릴벤조피란유도체및이를함유하는시클로옥시게네이즈-2저해제조성물
TW587079B (en) * 1998-09-25 2004-05-11 Almirall Prodesfarma Ag 2-phenylpyran-4-one derivatives
ES2208227T3 (es) * 1999-12-03 2004-06-16 Pfizer Products Inc. Compuestos de heteroarilfenilpirazol como agentes antiinflamatorios/analgesicos.
AU2001258677A1 (en) * 2000-05-22 2001-12-03 Dr. Reddy's Research Foundation Novel compounds having antiinflammatory activity: process for their preparation and pharmaceutical compositions containing them
ES2213485B1 (es) * 2003-02-13 2005-12-16 Almirall Prodesfarma, S.A. Derivados de la 2-fenilpiran-4-ona.
ES2214130B1 (es) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 2-3'-bipiridinas.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492416B1 (en) * 1999-04-14 2002-12-10 Pacific Corporation 4,5-diaryl-3(2H)-furanone derivatives as cyclooxygenase-2 inhibitors

Also Published As

Publication number Publication date
ES2214129B1 (es) 2005-12-01
ES2214129A1 (es) 2004-09-01
CN1771240A (zh) 2006-05-10
JP2006517561A (ja) 2006-07-27
EP1592678A1 (en) 2005-11-09
US20060189684A1 (en) 2006-08-24
WO2004072057A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
JPWO2010110231A1 (ja) 置換された３−ヒドロキシ−４−ピリドン誘導体
JP2005516009A (ja) 重水素化された置換ピラゾリル−ベンゼンスルホンアミド並びにこれを含有する医薬品
JP2002522541A (ja) ホスホジエステラーゼ４阻害剤としての置換１，８−ナフチリジン−４（１ｈ）−オン
CN86104539A (zh) 羟基和烷氧基嘧啶类
TWI635076B (zh) 吡咯衍生物之製造方法及其中間體
CN1602304A (zh) 氘代的取代的二氢呋喃酮以及包含该化合物的药物组合物
MXPA06002507A (es) Composiciones de modafinil.
CN100349884C (zh) 3－苯基呋喃－2－酮衍生物作为环加氧酶的抑制剂
CN1218459A (zh) 2－(3h)－噁唑酮衍生物及其作为cox－2抑制剂的应用
JP2000515161A (ja) 新規の炭素環式ジアリールメチレン誘導体、その製造方法及びその治療上の使用
JP6980779B2 (ja) 肝臓送達に基づく抗ウイルス性プロドラッグであるヌクレオシド環状リン酸エステル化合物およびその使用
CN1324352A (zh) 2－苯基吡喃－4－酮衍生物
EP0463944B1 (fr) Acyl benzoxazolinones, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
CN1255387C (zh) 可用作选择性cox－2抑制剂的嘧啶衍生物
JP5486008B2 (ja) １‐ブチル‐２‐ヒドロキシアラルキルピペラジン誘導体およびその抗鬱剤としての使用
JPH11506425A (ja) エチニルチアゾール誘導体
CN107922375A (zh) 靶向idh2突变的抗肿瘤化合物及其使用方法
US20050070579A1 (en) Crystals of taxane derivative and process for their production
US20060229338A1 (en) 2,3'-bipyridines derivatives as selective cox-2 inhibitors
CN107964013B (zh) 抗真菌剂
WO2017107791A1 (zh) 取代的氨基吡喃衍生物的晶型
CN100436438C (zh) 2-苯基吡喃-4-酮衍生物作为环加氧酶-2的抑制剂
JP2005529146A (ja) 中枢神経系障害の治療で使用するための実質的に純粋な固形型３−インドリルピルビン酸のエノール互変異性体
WO2024235167A1 (zh) 一种吡唑并吡嗪类化合物及其晶型的制备方法
HK1034183A1 (en) Galenic formulations of meloxicam for oral administration

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20071121

Termination date: 20100212